Characterizing the clinical and genetic spectrum of polycystic ovary syndrome in electronic health records

Short title: EHR-based analysis of PCOS

Ky'Era V. Actkins[1,2], Kritika Singh[2,3], Donald Hucks[2,3], Digna R. Velez Edwards[2,6,7], Melinda Aldrich[2,3,4,5], Jeeyeon Cha[8], Melissa Wellons[8], and Lea K. Davis[2,3]

[1] Department of Microbiology, Immunology, and Physiology, Meharry Medical College, Nashville, TN

[2] Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN

[3] Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

[4] Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN

[5] Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN

[6] Vanderbilt Epidemiology Center, Institute of Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN

[7] Division of Quantitative Sciences, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN

[8] Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

Corresponding author

Lea Davis
Assistant Professor of Medicine
Vanderbilt Genetics Institute
Division of Genetic Medicine
Department of Medicine
511-A Light Hall
Vanderbilt University
2215 Garland Ave
Nashville, TN 37232
Office Tel: 615-875-9478

Keywords: polycystic ovary syndrome, phenotyping, hormones, electronic health record, polygenic risk scores

47
48
49 Acknowledgements
50
51 **Funding/Support:** KVA and JC are supported by NIH training grant 5T32GM007628-42
52 and 5T32DK007061. LKD is supported by U54MD010722.
53
This research was done in part using the resources from the Advanced Computing
Center for Research and Education at Vanderbilt University, Nashville, TN. Datasets for
this project were obtained using the Synthetic Derivative at Vanderbilt University
Medical Center which is supported by multiple grant sources that are institutional,
private, and federal. This includes the NIH funded Shared Instrumentation Grant
S10RR025141 and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975.
60
61 **Authors contributions:** KVA and LKD drafted the manuscript. KVA, DH, and KS
62 performed chart review. JC and MW supervised and reviewed chart review. All authors
63 contributed to the interpretation of the data and the revision of the manuscript.
64
65 Disclosures
66
67 The authors have nothing to disclose.
68

Abstract

Context: Polycystic ovary syndrome (PCOS) is one of the leading causes of infertility,

yet current diagnostic criteria are ineffective at identifying patients whose symptoms

reside outside strict diagnostic criteria. As a result, PCOS is under diagnosed and its

etiology is poorly understood.

Objective: We aim to characterize the phenotypic spectrum of PCOS clinical features

within and across racial and ethnic groups.

Methods: We developed a strictly defined PCOS algorithm ($PCOS_{regex-strict}$) using

International Classification of Diseases, 9th and 10th edition (ICD9/10) and regular

expressions mined from clinical notes in electronic health records (EHRs) data. We then

systematically relaxed the inclusion criteria to evaluate the change in epidemiological

and genetic associations resulting in three subsequent algorithms ($PCOS_{coded-broad}$,

$PCOS_{coded-strict}$, $PCOS_{regex-broad}$). We evaluated the performance of each phenotyping

approach and characterized prominent clinical features observed in racially and

ethnically diverse PCOS patients.

Results: The best performing algorithm was our $PCOS_{coded-strict}$ algorithm with a positive

predictive value (PPV) of 98%. Individuals classified as cases by this algorithm had

significantly higher body mass index (BMI), insulin levels, free testosterone values, and

genetic risk scores for PCOS, compared to controls. Median BMI was higher in African

American women with PCOS compared to White and Hispanic women with PCOS.

Conclusions: PCOS symptoms are observed across a severity spectrum that parallels

genetic burden. Racial and ethnic group differences exist in PCOS symptomology and

metabolic health across different phenotyping strategies.

<u>Introduction</u>

Polycystic ovary syndrome (PCOS) is an endocrine disorder that is the leading

cause of infertility in women. The genetic, environmental, and metabolic variables that

contribute to its complex architecture also influence clinical heterogeneity among

individuals with PCOS, resulting in a broad spectrum of symptoms. The heterogenous

clinical presentation of PCOS makes it difficult to diagnose and an estimated 75% of

women with PCOS remain undiagnosed (1,2).

There are three commonly used diagnostic criteria for PCOS which each have

specific symptom requirements for diagnosis. The first diagnostic definition was put forth

by the National Institute of Health (NIH) who required an ovulatory phenotype (i.e.,

oligomenorrhoea) and hyperandrogenism for diagnosis (3,4). Subsequently, the second

diagnostic definition for PCOS was created by the European Society for Human

Reproduction and Embryology and the American Society for Reproductive Medicine,

which is commonly referred to as Rotterdam criteria. The Rotterdam diagnostic criteria

was designed to expand the PCOS definition from the strict NIH definition by requiring

any two out of the following three symptoms: oligoanovulation, hyperandrogenism, or

polycystic ovaries (3,5). However, the Androgen Excess and PCOS Society argued that

hyperandrogenism is the primary driver of PCOS and thus, created a third diagnostic

criteria that requires both hyperandrogenism and ovulatory dysfunction (i.e.,

oligoanovulation or polycystic ovaries) (4). PCOS diagnostic criteria were developed to

improve and standardize diagnosis, however, patients identified by each approach may

have differing symptomologies and only a small fraction of women will meet multiple

diagnostic criteria (6,7).

Implementing a broader PCOS definition could lead to false positive diagnoses

and prevalence overestimations (4,8). However, restrictive definitions miss women with

clinical manifestations outside of the requirements (9) including metabolic dysfunction.

Women with PCOS and metabolic dysfunction are at higher risk for a range of

comorbidities including insulin resistance, type 2 diabetes, cardiovascular disease,

obesity, cancer, and psychiatric disorders (10,11). Delayed screening and treatment for

PCOS could exacerbate these metabolic conditions, particularly in underrepresented

populations who have a greater baseline risk of metabolic disorders (12,13). Studies

have shown that African American and Hispanic women with PCOS have an increased

risk for metabolic syndrome and other cardiovascular disorders, yet little is known about

why comorbidities increase across diverse racial and ethnic groups and whether

expanding diagnostic criteria for PCOS may improve health equity (14,15).

Most prior studies included small numbers of minority women and many have

used differing diagnostic criteria (1,16–18). Without larger studies, it is difficult to

accurately characterize the clinical presentation of PCOS and its consequences across

populations. Adapting an inclusive phenotyping approach capable of identifying severe

to mild PCOS presentations could improve study methods for marginalized

communities.

The overarching hypothesis of this study is that clinically diagnosable PCOS

represents the extreme tail (i.e., clinical manifestation) of a spectrum of hormonal and

metabolic dysregulation with common manifestations in a large number of women. In

our study, we developed a simple but stringent automated phenotyping algorithm that

could be applied to electronic health records (EHRs) to identify women with confirmed

PCOS. Next, we systematically relaxed the inclusion criteria to test the hypothesis that

excess androgens, increased metabolic dysfunction, and PCOS genetic liability are

present to a lesser degree among women with PCOS symptoms outside diagnostic

criteria. Finally, we examined these features across diverse racial and ethnic groups

within the EHR.

Methods

Clinical data

Vanderbilt University Medical Center (VUMC) is a tertiary care hospital in

Nashville, Tennessee, with several clinics throughout Tennessee and the surrounding

states. Medical records have been electronically documented at VUMC since the early

1990s (19). The VUMC EHR houses over 2.8 million EHRs in a de-identified clinical

research database referred to as the Synthetic Derivative (SD). The SD includes

demographics, International Classification of Diseases, Ninth Revision (ICD9) and

Tenth Revision (ICD10) codes, procedural codes (CPT), clinical notes, medications, and

laboratory values. The Vanderbilt University Institutional Review Board approved this

project (IRB 160279).

Algorithm development

We identified women with PCOS within the SD using a strict automated

phenotyping algorithm that yielded a positive predictive value (PPV) of at least 90%.

Our secondary analyses relaxed the requirements of our core algorithm to identify a

larger sample of patients with a wider array of PCOS symptoms. In total, we developed

four algorithms which are illustrated in **Figure 1**. The demographics of each resultant

dataset is reported in **Table 1**.

Before applying each algorithm, we filtered the entire SD population to include

only females between the ages of 11 to 44 to enrich our population for females of

reproductive age. We first deployed the PCOS$_{regex-strict}$ algorithm which required at least

one ICD9 or ICD10 code for: polycystic ovaries (i.e., 256.4 and E28.2) OR hirsutism

(i.e., 704.1 and L68.0) AND irregular menses (i.e., all 626 codes, all N91 codes, N92.5,

and N92.6) **(Supplementary Table 1)**. Hirsutism was used as clinical evidence of

hyperandrogenism. Individuals with any exclusion codes **(Supplementary Table 1)**

present in their medical record were removed. Furthermore, the PCOS$_{regex-strict}$ algorithm

required the presence of at least one of the following regular expressions, "polycystic

ovaries", "PCOS", or "PCO " in a clinical note. We included inpatient and outpatient note

types designated as "Outpatient note", "Gynecology clinic visit", "Nursing report",

"Endocrine and Diabetes Clinic Visit", "Pediatric Endocrinology Patient Visit", and

"Reproductive Endocrinology Clinic Visit". Next, to broaden the approach, we dropped

the regular expression requirements and retained only the ICD codes for the PCOS$_{coded-}$

$_{strict}$ algorithm. We then loosened the requirement of the union of ICD codes and instead

required the presence of ICD codes for polycystic ovaries <u>OR</u> hirsutism <u>OR</u> irregular

menses. In addition to any code for these conditions, we required the presence of a

PCOS-related regular expression. The resultant algorithm was termed "PCOS$_{regex-broad}$".

Lastly, we again dropped the regular expression requirement which resulted in the

broadest approach (PCOS$_{coded-broad}$) including only the presence of ICD codes for

polycystic ovaries <u>OR</u> hirsutism <u>OR</u> irregular menses.

To identify controls, the SD was again filtered for females between the ages of 11

to 44. The control dataset excluded individuals with one or more exclusion ICD codes or

any inclusion codes used to define PCOS case criteria **(Supplementary Table 1)**.

Chart review methods for algorithm evaluation

We performed two comprehensive chart reviews to evaluate the performance of

the phenotyping algorithms. The charts were reviewed by clinical domain experts (MW

and JC) and trained reviewers (KVA, DH, and KS). We first evaluated the positive

predictive value (PPV) for each algorithm. We randomly selected 50 charts from each

set of algorithm defined cases (200 in total) for manual chart review. We then calculated

the proportion of true positive cases based on manual chart review out of the total

algorithm identified cases, to define the PPV for each algorithm (**Table 2**).

Next, we evaluated the sensitivity and specificity of the original PCOS$_{regex-strict}$

algorithm. For this review, we first identified a "medical home" population (defined by the

presence of at least 5 ICD codes on separate days over at least a 3-year period (N =

752,436)). Then, we filtered for females who met a data floor requirement (i.e., at least

one ICD10 code for PCOS, E28.2 (N = 9,507)). We then selected 200 charts at random

and performed manual chart review of all available information in the EHR (i.e., codes

and clinical notes) to classify individuals into "PCOS cases" and "not PCOS cases". This

manual review clinical determination was then compared to the PCOS$_{regex-strict}$ algorithm-

defined determination to calculate sensitivity and specificity (**Table 3**).

Laboratory data

Weight and height measurements are routinely recorded during clinical visits and

were extracted from the EHR to calculate body mass index (BMI). Laboratory

measurements were extracted and cleaned using QualityLab (20). In brief, 3,075

quantitative laboratory tests were extracted from EHRs of 70,704 patients in the SD.

Laboratory values with non-numeric values (n=2,865) and labs evaluated on only one

patient (n=467) were removed. The remaining labs were cleaned by filtering out

duplicate entries and measurements with multiple units. Insulin, estradiol, and free

testosterone hormone data was then extracted for further analysis. Median laboratory

values were calculated for individuals with multiple clinical measurements. Median

laboratory values of BMI, insulin, estradiol, and free testosterone were used to

characterize the clinical features of each algorithm dataset (**Table 4 and**

Supplementary Table 2). For each lab, extreme outliers (i.e., 1st and 99th percentile)

were removed. Additionally, lab values were regressed on age at lab and an inverse

normal transformation was applied to the residual to result in an age-adjusted

normalized lab value for subsequent analysis including genetic analysis

(**Supplementary Table 5**). Sample sizes differed for subsequent analyses based on

available clinical measurements (**Supplementary Figure 1**).

G*enetic data*

We included 40,006 females of European descent and 7,736 females of non-

European descent who were genotyped on the Illumina MEGA[EX] Array (Illumina Inc,

San Diego, CA) (21). We removed SNPs with a call rate < 0.98, individuals with a call

rate of < 0.98, and individuals with a discrepancy between chromosomal and reported

sex. EIGENSTRAT was used for principal component analysis (PCA) (22,23). Related

samples with a pi-hat > 0.2 (approximate first cousin relationships) were removed. The

Michigan Imputation server was used to impute missing genotypes based on the

Haplotype Reference Consortium panel and imputation accuracy was set at $R^2 > 0.03$

(24).

Construction of PCOS polygenic risk scores (PCOS$_{PRS}$)

Polygenic risk scores (PRS) for PCOS were calculated for each individual using

the PRS-CS software package, which applies a Bayesian continuous shrinkage model

to SNP beta estimates (25). Beta estimates were drawn from summary statistics of the

largest meta-GWAS of PCOS performed by Day et al. which included 5,209 cases and

32,055 controls of European descent diagnosed using NIH or Rotterdam criteria (26).

PCOS$_{PRS}$ were calculated for a total of 36,487 females of European descent, 5,582 non-

European descent females, and 29,511 females from multiple ancestries in BioVU.

Statistical Analysis

The prevalence of each algorithm was calculated using the proportion of cases

identified by each algorithm among total number of EHRs (**Table 2**). The PPV was

determined by calculating the proportion of "reviewer-defined" true positives among

"algorithm-defined" positives (**Table 2**). Sensitivity was defined as the number of

"algorithm-defined" positives out of the total positives (i.e., "algorithm-defined" positives

plus "reviewer-defined" positives). Specificity was defined as the number of "algorithm-

defined" negatives out of the total negatives (i.e., "algorithm defined and "reviewer-

defined" negatives) (**Table 3**).

We performed Wilcoxon rank-sum tests to determine if the median BMI and

laboratory measurements (e.g., free testosterone, insulin, and estradiol) differed

between the PCOS algorithm-identified cases and controls. We then tested the

difference between cases defined by each algorithm and between cases and controls

stratified by EHR-reported race. Finally, we evaluated differences between African

American, White, and Hispanic women identified as cases by each algorithm (**Table 4,**

Supplementary Table 2, Figures 2-4, Supplementary Figures 2-3).

We performed logistic and linear regression analyses to test the association

between PCOS$_{PRS}$ and case/control designation and, separately, the association

between PCOS$_{PRS}$ and available hormone data (i.e., estradiol, free testosterone,

insulin). The analysis was performed in three populations based on genetic ancestry:

European descent (n=6,930), non-European (n = 2,050), and multi-ancestry (n=7,135).

Our multi-ancestry cohort includes all genotyped individuals (European and non-

European descent). Covariates included median age (calculated across the medical

record for each individual) and top ten principal components of ancestry for the

case/control logistic regression model. A separate sensitivity analysis adjusting BMI was

also performed (**Supplementary Table 3**). For regression analysis of hormone data,

covariates included the top ten principal components of ancestry. We then evaluated

the model and variance explained by PCOS$_{PRS}$ using Nagelkerke's pseudo R^2 for the

logistic regressions and R^2 for the linear regressions (**Table 5**, **Supplementary Table 3-**

4). All of the analyses were done in R 3.3.3.

We included two corrections for multiple testing. The first corrected threshold

reflects adjustment for each of the independent tests (n = 30, p < 0.002, indicated by *

in tables). The second corrected threshold is more stringent and reflects adjustment for

each of the tests (n = 120, $p < 4\times10^{-3}$, indicated by ** in tables) regardless of whether

they were independent or performed on nested subsets of the data (**Figure 1**).

Results

Sample Characteristics

PCOS dataset demographics are reported in **Table 1**. Although the sample sizes

differed between the algorithms, each algorithm identified a similar proportion of

individuals across racial/ethnic groups. The most stringent algorithm, PCOS$_{regex-strict}$,

identified 4,593 potential PCOS cases including 3,143 White, 658 African American and

204 Hispanic women (**Table 2**). As the algorithm requirements were relaxed, the

number of identified PCOS cases increased. $PCOS_{regex-broad}$ identified 6,193 individuals

including 4,207 White, 899 African American, and 274 Hispanic women. The $PCOS_{coded-strict}$

approach identified 8,340 individuals including 5,526 White, 1,217 African American,

and 368 Hispanic women. At the broadest extreme, the $PCOS_{coded-broad}$ (n = 41,205)

algorithm captured the largest and most diverse sample with 26,317 White, 7,648

African American, and 2,052 Hispanic women.

The individuals identified by the regex algorithms had the highest average

medical record length at 4.69 years (SD = 4.22) for $PCOS_{regex-broad}$ and 4.66 years (SD =

4.13) for $PCOS_{regex-strict}$. This was expected as the increased length of record also

increased the probability of PCOS documentation in the medical record. The $PCOS_{coded-strict}$

and $PCOS_{regex-strict}$ algorithms captured the eldest set of patients who were in their

mid 20s with a median age of 25.18 (SD = 7.63) and 25.09 (SD = 7.39), respectively.

Comparatively, the control dataset had the youngest sample aged 23.85 (SD = 9.47)

with the shortest EHR record length at 3.92 (SD = 3.9). As expected, the control sample

had the lowest average clinical measurements for BMI, insulin, estradiol, and free

testosterone.

Evaluation of algorithm performance

We found little difference between the PPVs calculated for the $PCOS_{regex-strict}$

algorithm using two distinct chart review methods. $PCOS_{regex-strict}$ yielded a PPV of 96%

using our first method of chart review (**Table 2**) and a PPV of 95% when it was tested

against the gold standard definition in our second manual review method (**Table 3**).

Despite this, PCOS$_{regex-strict}$ algorithm had a sensitivity of only 50% and specificity of

29% when evaluated using the gold standard definition (**Table 3**).

When compared to our broader algorithms, the performance of the PCOS$_{regex-strict}$

algorithm was most similar to the PCOS$_{coded-strict}$ algorithm which had a slightly higher

PPV of 98% (**Table 2**). The text mining criteria did not significantly improve the accuracy

of PCOS$_{regex-strict}$ over PCOS$_{coded-strict}$. The accuracy of the "broad" criteria decreased

compared to the "strict" algorithms. Our broadest algorithm, PCOS$_{coded-broad}$, had the

lowest performance with a PPV of 30% (**Table 2**). This is likely due to the large number

of patients who only had an irregular menstruation ICD code with no other diagnosed

PCOS symptoms. Interestingly, the addition of the text-mined PCOS keyword

significantly improved the PPV of the broad criteria algorithm from 30% (PCOS$_{coded-broad}$)

to 82% (PCOS$_{regex-broad}$). Unlike the extreme broad criteria, the other algorithms had a

PCOS prevalence that reflected the prevalence observed in the population (18,27,28).

This was also true for the race stratified cohorts where there were little to no differences

in prevalence.

Clinical feature characterization

We characterized the clinical profiles of cases and controls identified by each

algorithm by calculating median BMI, insulin, estradiol, and free testosterone levels

(**Table 4**). Each algorithm identified set was significantly heavier compared to controls

(p < 0.05). For all algorithms, African American and Hispanic women had higher

baseline metabolic profiles for BMI, insulin, estradiol, and free testosterone

measurements compared to White women (1,2). Moreover, the median BMI in the

algorithm datasets increased with increasing algorithm stringency (**Figure 2a**). African

American women meeting algorithm criteria consistently demonstrated the highest

median BMI in the $PCOS_{coded-broad}$, $PCOS_{coded-strict}$, and $PCOS_{regex-broad}$ algorithms

(**Supplementary Table 2**). The BMI of all three stratified race groups differed

significantly from each other with the exception of White and Hispanic women in the

strictest regex algorithms (**Figure 3a)**. Within the Hispanic defined group, the median

values did not vary significantly between the $PCOS_{coded-strict}$, $PCOS_{regex-broad}$, and

$PCOS_{regex-strict}$ groups (**Supplementary Figure 3a**).

Overall, women identified by each of the four PCOS algorithms demonstrated

significantly higher insulin and free testosterone levels compared to controls ($p < 0.05$)

(**Figures 2b, 2d, Table 4**). The median hormone values also increased with algorithm

stringency, though the trend was not as pronounced as it was for the BMI

measurements. BMI increased with algorithm stringency within each race stratified

analysis. Insulin values increased with algorithm stringency for White and Hispanic

women, and free testosterone values increased with algorithm stringency for White and

African American women (**Figure 4**, **Supplementary Table 2**).

Measurements of free testosterone were significantly higher among women

identified by the $PCOS_{coded-strict}$, $PCOS_{regex-broad}$ and $PCOS_{regex-strict}$ algorithms compared

to the controls and the $PCOS_{coded-broad}$ algorithm (**Supplementary Figure 2d**). The

insulin profile of African Americans was similar across women identified by each

algorithm and also did not significantly differ from controls (**Figure 4b**). However,

African American women identified by the PCOS$_{coded-broad}$ and PCOS$_{regex-broad}$ algorithms

did exhibit higher estradiol levels than African American controls (**Figure 4c**).

Additionally, African American women identified by the PCOS$_{regex-broad}$ algorithm

demonstrated significantly higher estradiol levels than White women identified by the

same approach (**Figure 3c**). Outside of these findings, there were no other significant

differences between races for hormone values (**Figure 3**).

Genetic validation of PCOS case status

Increasing algorithm requirement stringency was also reflected in the

performance of the PCOS$_{PRS}$. Odds ratios (ORs), which are reported per standard

deviation of the PCOS$_{PRS}$ were higher among cases identified by algorithms using strict

PCOS requirements and decreased as those requirements were relaxed. This trend

was observed for both the European and multi-ancestry genotyped samples (**Figure 5,**

Table 5). BMI was tested as a covariate in the model and did not impact the results.

(**Supplementary Table 3**).

Among European genotyped cases identified by the PCOS$_{regex-broad}$ algorithm we

observed an OR of 1.29 (p = 4.6E-5) and the greatest variance explained in

case/control status by the PCOS$_{PRS}$ model (pseudo-r^2 = 0.83%, p = 4.6E-5) (**Table 5**).

When the PCOS$_{PRS}$ model was applied to the multi-ancestry sample, the PCOS$_{coded-broad}$

yielded the highest OR (OR = 1.49, p = 8.7E-5), followed by PCOS$_{regex-strict}$ (OR = 1.44,

p = 0.003) and PCOS$_{regex-broad}$ (OR = 1.41, p = 0.001). The PCOS$_{coded-strict}$ algorithm

(pseudo-r^2 = 0.7%, p = 8.7E-5) also had the most variance explained by the model.

Similar to the European genotyped sample, only the PCOS$_{regex-broad}$ and the PCOS$_{coded-}$

$_{strict}$ algorithm passed at least one of our two multiple correction tests.

There were no significant associations between PCOS$_{PRS}$ and case/control

status within the non-European genotyped sample. We are underpowered in this

analysis, which is evidenced by large confidence intervals in comparison to the

European and multi-ancestry genotyped sample (**Figure 5, Table 5**).

Association between PCOS$_{PRS}$ *and hormone measurements*

There was no association between PCOS$_{PRS}$ and any of the hormone measures

(insulin, estradiol, and free testosterone) evaluated. (**Supplementary Tables 4-6**).

Discussion

Expanding study inclusion criteria has the potential to increase and diversify

future study samples which may significantly benefit underrepresented high risk groups

(27). This study describes an automated PCOS phenotyping method that captures

varying degrees of PCOS symptoms, parallel dysregulated hormone levels, and

increased genetic risk for the PCOS$_{coded-strict}$, PCOS$_{regex-broad}$, and PCOS$_{regex-strict}$

algorithms. Our results also further support the hypothesis that women with PCOS

symptoms have increased metabolic dysregulation compared to controls when

measured on BMI, insulin, and free testosterone values dependent on clinical definitions

and their EHR-reported race. Finally, our study demonstrates the importance of

including multiethnic genotyped samples in addition to European populations, for

genetic analysis.

Our two "strict definition" algorithms identified PCOS cases with high accuracy

(PPV>95%) and the PCOS$_{regex-strict}$ algorithm performed just as well when compared to

the gold standard dataset (PPV = 95%). Although the sensitivity and the specificity of

the PCOS$_{regex-strict}$ algorithm was low, the high PPV displays its high accuracy within an

EHR setting. Compared to the previously reported ICD based PCOS algorithm, which

had a PPV of 66% and 65% for their "broad" and "refined" algorithm, our two best

performing algorithms improved case identification by over 30% (9). Both the Castro et

al. study and our study show the feasibility of using ICD based algorithms to identify

PCOS cases and the advantages of using EHR systems. Consistent with the previous

study, we also found that inclusion of text mining increased the proportion of true PCOS

cases (PPV = 98%) but resulted in a smaller sample size. Removal of the text mining

requirement only slightly impacted the PPV (96%), indicating that studies performed in

EHR systems with limited access to clinical notes and ultrasound images may still be

able to identify women with PCOS with high accuracy. Conversely, we found that the

addition of text mining to the broad algorithms significantly improved the accuracy from

30% to 82%, indicating that clinical suspicions of PCOS documented in medical records

may also be used to identify women with PCOS even when few symptoms are coded.

The clinical and epidemiological features of our PCOS cohorts are consistent

with previous studies that show women with PCOS have higher metabolic clinical

characteristics than controls (29–31). We also observed no significant difference in the

prevalence of PCOS definitions between minority and White individuals, nor were there

any large differences between races for insulin, estradiol, and free testosterone clinical

measurements (32). However, African American had significantly higher BMI

measurements than Hispanic and White women across both the control and PCOS

definition datasets. African Americans are disproportionately affected by conditions such

as obesity and type 2 diabetes, which could possibly be exacerbated by the onset of

PCOS (33,34). These conditions could also be influenced by the patient structure of the

EHR database which will have a sicker population due to the tertiary care status of

VUMC and due to its geographic location where obesity rates are generally higher.

Polygenic risk scores provide the unique ability to examine the genetic

susceptibility of PCOS across different clinical definitions and ancestries. However, it is

important to note that, as of to date, there are no PCOS GWAS in African descent

populations, and that PRS built from Eurocentric populations will not perform as robustly

in non-European samples (35). Despite this, previous studies have shown that

$PCOS_{PRS}$ models can detect cross-ancestry genetic risk in African and multi-ancestry

cohorts using European based PRS models (36). In our study, the $PCOS_{PRS}$ model

explained little variance in case/control status (pseudo-r^2 < 1%), but the $PCOS_{PRS}$ was

significantly higher among cases in the $PCOS_{coded-strict}$, $PCOS_{regex-broad}$, and the

$PCOS_{regex-strict}$ algorithms compared to controls.

Eurocentric GWAS remain a significant limitation to interpretability of PRS in non-

European samples and studies including genetic data gathered on diverse ancestral

populations are needed to advance PCOS genomics in the EHR (35,37). The limitations

of our study include low statistical power in the genetic analysis of non-European cases

and controls. This limitation is primarily a function of the under-representation of non-

European populations in the PCOS GWAS, but also reflects the low representation of

non-European samples in the VUMC EHR.

In conclusion, we applied an automated phenotyping approach to examine

variation in the symptomology of PCOS across racial and ethnic groups using both strict

and broad classification criteria. Debate over current implemented PCOS diagnostic

criteria, in part, reflects the complexity of PCOS symptoms and EHRs provide significant

advantages. First, research in the longitudinal EHR allows us to maximize the number

of PCOS clinical manifestations observed over time (16,28,38). Secondly, EHRs contain

a variety of clinical variables (e.g., laboratory measurements, imaging records, etc.) that

can be used to study the risk factors and health outcomes of PCOS patients. We

created a simple EHR-based PCOS algorithm that identifies patients using ICD codes

and text mining ($PCOS_{regex\text{-}strict}$) methods and by relaxing the inclusion requirements we

identified patients across the PCOS syndromic spectrum. This study approach provides

a unique view of the shared clinical and genetic architecture that influences both PCOS

as a discrete diagnosis, and the symptoms of PCOS that affect a large number of

women.

References

1.   **Wolf WM, Wattick RA, Kinkade ON, Olfert MD.** Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. *Int. J. Environ. Res. Public Health* 2018;15(11):2589.

2.   **Teede H, Gibson-Helm M, Norman RJ, Boyle J.** Polycystic Ovary Syndrome: Perceptions and Attitudes of Women and Primary Health Care Physicians on Features of PCOS and Renaming the Syndrome. *J Clin Endocrinol Metab* 2014;(1):99.

3.   **ESHRE TR, Group A-SPCW.** Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil. Steril.* 2004;81(1):19–25.

4.   **Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale F, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF, (Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society)∗, Ector H, Escobar-Morreale F, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF.** The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertil. Steril.* 2009;91(2):456–488.

5.   **Indran IR, Huang Z, Khin LW, Chan JK, Viardot-Foucault V, Yong EL.** Simplified 4-item criteria for polycystic ovary syndrome: A bridge too far? *Clin. Endocrinol. (Oxf).* 2018;89(2):202–211.

6.   **Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, Teede HJ.** Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. *Hum. Reprod.* 2013;28(3):777–784.

7.   **Hickey M, Doherty DA, Atkinson H, Sloboda DM, Franks S, Norman RJ, Hart R.** Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: Implications for diagnosis. *Hum. Reprod.* 2011;26(6):1469–1477.

8.   **Copp T, Jansen J, Doust J, Mol BW, Dokras A, McCaffery K.** Are expanding disease definitions unnecessarily labelling women with polycystic ovary syndrome? *BMJ* 2017;358. doi:10.1136/bmj.j3694.

9.   **Castro V, Shen Y, Yu S, Finan S, Pau CT, Gainer V, Keefe CC, Savova G, Murphy SN, Cai T, Welt CK.** Identification of subjects with polycystic ovary syndrome using electronic health records. *Reprod. Biol. Endocrinol.* 2015;13(1):1–8.

10. **Jacewicz-Święcka M, Kowalska I.** Polycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies. *Diabetes. Metab. Res. Rev.* 2018;34(8). doi:10.1002/dmrr.3054.

11. **Pavicic Baldani D, Skrgatic L, Ougouag R.** Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women. 2015. doi:10.1155/2015/786362.

12. **Chan JL, Kar S, Vanky E, Morin-Papunen L, Piltonen T, Puurunen J, Tapanainen JS, Maciel GAR, Hayashida SAY, Soares Jr JM.** Racial and ethnic differences in the prevalence of metabolic syndrome and its components of metabolic syndrome in women with polycystic ovary syndrome: a regional cross-

sectional study. *Am. J. Obstet. Gynecol.* 2017;217(2):189. e1-189. e8.

13. **Engmann L, Jin S, Sun F, Legro RS, Polotsky AJ, Hansen KR, Coutifaris C,**
Diamond MP, Eisenberg E, Zhang H, Santoro N. Racial and ethnic differences
in the polycystic ovary syndrome metabolic phenotype. 2017.
doi:10.1016/j.ajog.2017.01.003.

14. **Meyer ML, Sotres-Alvarez D, Steiner AZ, Cousins L, Talavera GA, Cai J,**
Daviglus ML, Loehr LR. Polycystic ovary syndrome signs and metabolic
syndrome in premenopausal Hispanic/Latina women: The HCHS/SOL study. *J.*
Clin. Endocrinol. Metab. 2020. doi:10.1210/clinem/dgaa012.

15. **Hillman JK, Johnson LNC, Limaye M, Feldman RA, Sammel M, Dokras A.**
Black women with polycystic ovary syndrome (PCOS) have increased risk for
metabolic syndrome and cardiovascular disease compared with white women with
PCOS. *Fertil. Steril.* 2014;101(2):530–535.

16. **March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ.** The
prevalence of polycystic ovary syndrome in a community sample assessed under
contrasting diagnostic criteria. *Hum. Reprod.* 2010;25(2):544–551.

17. **Ding T, Hardiman PJ, Petersen I, Wang F-F, Qu F, Baio G.** The prevalence of
polycystic ovary syndrome in reproductive- aged women of different ethnicity: a
systematic review and meta-analysis. *Oncotarget* 2017;8(56):96351–96358.

18. **Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO.** The prevalence
and phenotypic features of polycystic ovary syndrome: A systematic review and
meta-Analysis. *Hum. Reprod.* 2016;31(12):2841–2855.

19. **Robinson JR, Wei W-Q, Roden DM, Denny JC.** Defining phenotypes from
clinical data to drive genomic research. *Annu. Rev. Biomed. Data Sci.* 2018;1:69–
92.

20. **Dennis JK, Sealock JM, Straub P, Hucks D, Actkins K, Faucon A, Goleva SB,**
Nirachou M, Singh K, Morley T, Ruderfer DM, Mosley JD, Chen G, Davis LK.
Lab-wide association scan of polygenic scores identifies biomarkers of complex
disease. *medRxiv* 2020:2020.01.24.20018713.

21. **Bien SA, Wojcik GL, Zubair N, Gignoux CR, Martin AR, Kocarnik JM, Martin**
LW, Buyske S, Haessler J, Walker RW, Cheng I, Graff M, Xia L, Franceschini
N, Matise T, James R, Hindorff L, Le Marchand L, North KE, Haiman CA,
Peters U, Loos RJF, Kooperberg CL, Bustamante CD, Kenny EE, Carlson
CS. Strategies for Enriching Variant Coverage in Candidate Disease Loci on a
Multiethnic Genotyping Array. *PLoS One* 2016;11(12):167758.

22. **Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D.**
Principal components analysis corrects for stratification in genome-wide
association studies. *Nat. Genet.* 2006;38(8):904–909.

23. **Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ.** Second-
generation PLINK: rising to the challenge of larger and richer datasets.
Gigascience 2015;4(7):7.

24. **Das S, Forer L, Schönherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew**
EY, Levy S, McGue M, Schlessinger D, Stambolian D, Loh PR, Iacono WG,
Swaroop A, Scott LJ, Cucca F, Kronenberg F, Boehnke M, Abecasis GR,
Fuchsberger C. Next-generation genotype imputation service and methods. *Nat.*
Genet. 2016;48(10):1284–1287.

25.   **Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW.** Polygenic prediction via
568   Bayesian regression and continuous shrinkage priors. *Nat. Commun.*
569   2019;10(1776):1–10.
570   26.   **Day F, Karaderi T, Jones MR, Meun C, He C, Drong A, Kraft P, Lin N, Huang**
571   **H, Broer L.** Large-scale genome-wide meta-analysis of polycystic ovary
572   syndrome suggests shared genetic architecture for different diagnosis criteria.
573   *PLoS Genet.* 2018;14(12):e1007813.
574   27.   **Neven ACH, Laven J, Teede HJ, Boyle JA.** A summary on polycystic ovary
575   syndrome: Diagnostic criteria, prevalence, clinical manifestations, and
576   management according to the latest international guidelines. *Semin. Reprod.*
577   *Med.* 2018;36(1):5–12.
578   28.   **Skiba MA, Islam RM, Bell R, Davis SR.** Understanding variation in prevalence
579   estimates of polycystic ovary syndrome: a systematic review and meta-analysis.
580   *Hum. Reprod. Update* 2018;7(1). doi:10.1093/humupd/7.1.1.
581   29.   **Lerchbaum E, Schwetz V, Rabe T, Giuliani A, Obermayer-Pietsch B.**
582   Hyperandrogenemia in Polycystic Ovary Syndrome: Exploration of the Role of
583   Free Testosterone and Androstenedione in Metabolic Phenotype. 2014.
584   doi:10.1371/journal.pone.0108263.
585   30.   **Antonio L, Pauwels S, Laurent MR, Vanschoubroeck D, Jans I, Billen J,**
586   **Claessens F, Decallonne B, De Neubourg D, Vermeersch P, Vanderschueren**
587   **D.** Free Testosterone Reflects Metabolic as well as Ovarian Disturbances in
588   Subfertile Oligomenorrheic Women. *Int. J. Endocrinol.* 2018.
589   doi:10.1155/2018/7956951.
590   31.   **Diamanti-Kandarakis E, Dunaif A.** Insulin Resistance and the Polycystic Ovary
591   Syndrome Revisited: An Update on Mechanisms and Implications. 2012.
592   doi:10.1210/er.2011-1034.
593   32.   **Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers**
594   **LM, Williams NI, Coney P, Legro RS.** Racial Influence on the Polycystic Ovary
595   Syndrome Phenotype: A Black White Case-Control Study. *Fertil Steril*
596   2011;96(1):224–229.
597   33.   **Huddleston HG, Cedars MI, Sohn SH, Giudice LC, Fujimoto VY.** Racial and
598   ethnic disparities in reproductive endocrinology and infertility. *Am. J. Obstet.*
599   *Gynecol.* 2010;202(5):413–419.
600   34.   **Butts SF, Seifer DB.** Racial and ethnic differences in reproductive potential
601   across the life cycle. *Fertil. Steril.* 2010;93(3):681–690.
602   35.   **Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ.** Clinical use of
603   current polygenic risk scores may exacerbate health disparities. 2019;51(4):584–
604   591.
605   36.   **Joo YY, Actkins K, Pacheco JA, Basile AO, Carroll R, Crosslin DR, Day F,**
606   **Denny JC, Velez Edwards DR, Hakonarson H, Harley JB, Hebbring SJ, Ho K,**
607   **Jarvik GP, Jones M, Karderi T, Mentch FD, Meun C, Namjou B, Pendergrass**
608   **S, Ritchie MD, Stanaway IB, Urbanek M, Walunas TL, Smith M, Chisholm RL,**
609   **Kho AN, Davis L, Hayes MG.** A polygenic and phenotypic risk prediction for
610   Polycystic Ovary Syndrome evaluated by Phenome-wide association studies. *J.*
611   *Clin. Endocrinol. Metab.* 2020. doi:10.1210/clinem/dgz326.
612   37.   **Wojcik GL, Graff M, Nishimura KK, Tao R, Haessler J, Gignoux CR, Highland**

HM, Patel YM, Sorokin EP, Avery CL, Belbin GM, Bien SA, Cheng I, Cullina S, Hodonsky CJ, Hu Y, Huckins LM, Jeff J, Justice AE, Kocarnik JM, Lim U, Lin BM, Lu Y, Nelson SC, Park S-SLSL, Poisner H, Preuss MH, Richard MA, Schurmann C, Setiawan VW, Sockell A, Vahi K, Verbanck M, Vishnu A, Walker RW, Young KL, Zubair N, Acuña-Alonso V, Ambite JL, Barnes KC, Boerwinkle E, Bottinger EP, Bustamante CD, Caberto C, Canizales-Quinteros S, Conomos MP, Deelman E, Do R, Doheny K, Fernández-Rhodes L, Fornage M, Hailu B, Heiss G, Henn BM, Hindorff LA, Jackson RD, Laurie CACC, Laurie CACC, Li Y, Lin D-YY, Moreno-Estrada A, Nadkarni G, Norman PJ, Pooler LC, Reiner AP, Romm J, Sabatti C, Sandoval K, Sheng X, Stahl EA, Stram DO, Thornton TA, Wassel CL, Wilkens LR, Winkler CA, Yoneyama S, Buyske S, Haiman CA, Kooperberg C, Le Marchand L, Loos RJFF, Matise TC, North KE, Peters U, Kenny EE, Carlson CS. *Genetic analyses of diverse populations improves discovery for complex traits*. Nature Publishing Group; 2019:514–518.

38. **Wang S, Alvero R.** Racial and ethnic differences in physiology and clinical symptoms of polycystic ovary syndrome. *Semin. Reprod. Med.* 2013;31(5):365–369.

 Figure Legends

Figure 1. PCOS algorithm pipeline. This schematic illustrates the algorithm

development steps for the controls and the four PCOS algorithms. The Venn diagram

illustrates how the algorithm datasets are nested within one another. Each color

corresponds with one of the algorithm datasets. ICD = International classification of

disease, 9th and 10th revision.

Figure 2. Laboratory measurements for PCOS algorithm cases and controls.

Boxplots of (a) BMI measurements, (b) insulin levels, (c) estradiol levels, and (d) free

testosterone levels for PCOS algorithm cases and controls. Colored boxes represent

races. Boxes represent the individuals with lab measurements in the 25th and 75th

percentile. Lines above and below the boxes represent the 95th and 5th quartiles. Lines

within each box mark the median. Wilcoxon rank-sum tests were performed between

algorithm cases and controls and Brackets display the p-values of the statistical test.

BMI= body mass index.

Figure 3. Comparison of laboratory measurements between White, African

American, and Hispanic PCOS algorithm cases and controls. Boxplots of (a) BMI

measurements, (b) insulin levels, (c) estradiol levels, and (d) free testosterone levels for

White, African American, and Hispanic PCOS cases and controls. Colors correspond

with each race. Boxes represent the 25th and 75th quartiles. Lines above and below the

boxes represent the 95th and 5th quartiles. Lines within each box mark the median.

Wilcoxon rank-sum tests were performed between races within the PCOS cases and

control datasets. Brackets display the p-values of the statistical test. BMI= body mass

index; W = White; AA = African American; HIS = Hispanic.

Figure 4. Race stratified laboratory measurements for PCOS algorithm cases and

controls. Boxplots of (a) BMI measurements, (b) insulin levels, (c) estradiol levels, and

(d) free testosterone levels of race stratified PCOS algorithm datasets. Each color

corresponds with a race. Boxes represent the 25th and 75th quartiles. Lines above and

below the boxes represent the 95th and 5th quartiles. Lines within each box mark the

median. Wilcoxon rank-sum tests were performed between algorithm cases and

controls within each race. Brackets display the p-values of the statistical test. BMI= body

mass index; CN = controls; CB = coded broad; CS = coded strict; RB = regex broad; RS

= regex strict.

Figure 5. Genetic validation of PCOS algorithms. Logistic regressions were

performed between PCOS case status and PCOS polygenic risk scores ($PCOS_{PRS}$).

The regression models were adjusted for median age and the first 10 principal

components. P-values are displayed for each regression model. Colors correspond to

the genotyped sample used in the analysis. OR = odds ratio.

Table 1. PCOS algorithm descriptive statistics. Descriptive statistics of women identified as PCOS cases and controls are provided. SD = standard deviation; EHR = electronic health record. NH = non-Hispanic, HIS = Hispanic.

	Controls	Coded Broad	Coded Strict	Regex Broad	Regex Strict
N	29140	41205	8340	6193	4593
NH White	22569	25977	5418	4154	3101
NH African American	3278	7555	1195	887	648
Hispanic	1421	2053	368	274	204
HIS White	1014	1462	264	203	154
HIS African American	33	69	13	11	8
Average Age (SD)	23.85 (9.47)	24.96 (7.97)	25.18 (7.63)	24.71 (7.52)	25.09 (7.39)
Average EHR Record Length (SD)	3.92 (3.9)	4.52 (4.54)	4.23 (4.15)	4.69 (4.22)	4.66 (4.13)
Medical Home (%)	65%	64%	60%	66%	66%
Average Clinical Values (SD)					
Body Mass Index	25.71 (7.43)	28.61 (8.44)	34.12 (9.10)	33.50 (9.14)	34.54 (9.07)
Insulin (mcU/mL)	20.08 (18.99)	24.86 (22.83)	27.17 (23.05)	25.34 (21.94)	27.27 (21.58)
Estradiol (pg/mL)	82.22 (69.03)	89.92 (69.74)	75.92 (61.13)	71.64 (56.56)	75.57 (60.49)
Free Testosterone (pg/mL)	3.58 (2.45)	4.70 (2.94)	5.70 (3.23)	5.41 (3.01)	5.73 (3.09)

Table 2. Prevalence for PCOS algorithms and chart review results. Prevalence of PCOS was calculated for everyone identified in each algorithm (overall) and for White, African American, and Hispanic women identified in each algorithm. Chart review was conducted on 50 random records identified by each PCOS algorithm (n = 200) and algorithm performance was measured through PPV. PPV = positive predictive value.

	Coded Broad	Coded Strict	Regex Broad	Regex Strict
Overall				
N	41205	8340	6193	4593
Prevalence	46%	9.3%	6.9%	5.1%
PPV	30%	98%	82%	96%
White				
N	26317	5526	4207	3143
Prevalence	50%	10.5%	8%	4.8%
African American				
N	7648	1217	899	658
Prevalence	65.9%	10.5%	7.8%	5.7%
Hispanic				
N	2052	368	274	204
Prevalence	48%	8.6%	6.4%	4.8%

Table 3. Sensitivity and specificity for PCOS algorithm datasets. A 2x2 contingency table showing the PPV, NPV, sensitivity, and specificity of the regex strict (RS) algorithm. The RS algorithm was compared to the gold standard definition. Chart review was conducted on 200 random records from females who met our data floor and medical home definition. PPV = positive predictive value; NPV = negative predictive value.

		Regex Strict Algorithm		
		Case	Not Case	**Results**
Gold Standard	Case	96	97	50% Sensitivity
	Not case	5	2	29% Specificity
	Results	95% PPV	2% NPV	

Table 4. Laboratory measurements for PCOS algorithm cases and controls. Wilcoxon rank sum test was performed between cases and controls. The 25th and 75th percentile was reported for each algorithm. BMI = body mass index.

Algorithm	Type	N	Median	25th Percentile	75th Percentile	P	
BMI							
Coded Broad	Cases	34603	26.54	22.21	33.50	< 2.22E-16	**
	Controls	29140	24.03	20.68	29.30		
Coded Strict	Cases	7555	33.605	27.28	40.36	< 2.22E-16	**
	Controls	29140	24.03	20.68	29.30		
Regex Broad	Cases	5844	32.805	26.29	39.70	< 2.22E-16	**
	Controls	29140	24.03	20.68	29.30		
Regex Strict	Cases	4358	34.08	27.63	40.76	< 2.22E-16	**
	Controls	29140	24.03	20.68	29.30		
Insulin							
Coded Broad	Cases	257	17.4	10.00	24.10	0.0001	**
	Controls	14475	13.65	5.50	20.90		
Coded Strict	Cases	150	19.05	11.20	28.70	1.50E-06	**
	Controls	14475	13.65	5.50	20.90		
Regex Broad	Cases	134	18.1	10.52	26.06	0.00088	*
	Controls	14475	13.65	5.50	20.90		
Regex Strict	Cases	109	19.4	11.53	32.53	2.40E-05	**
	Controls	14475	13.65	5.50	20.90		
Estradiol							
Coded Broad	Cases	196	63.5	38.00	116.00	0.0081	
	Controls	18799	55.5	32.00	108.00		
Coded Strict	Cases	67	54	38.00	96.65	0.79	
	Controls	18799	55.5	32.00	108.00		
Regex Broad	Cases	58	54.5	38.50	90.88	0.86	
	Controls	18799	55.5	32.00	108.00		
Regex Strict	Cases	48	55.5	39.50	93.20	0.64	
	Controls	18799	55.5	32.00	108.00		
Free Testosterone							
Coded Broad	Cases	159	4.4	2.25	6.58	0.0016	*
	Controls	125	3	1.70	4.95		
Coded Strict	Cases	75	5.9	3.00	7.70	3.80E-06	**
	Controls	125	3	1.70	4.95		
Regex Broad	Cases	73	5.2	2.90	7.40	3.50E-05	**
	Controls	125	3	1.70	4.95		
Regex Strict	Cases	53	5.6	3.60	7.50	1.40E-05	**
	Controls	125	3	1.70	4.95		

Table 5. Genetic validation of PCOS diagnosis. Logistic regressions were performed between PCOS case status and PCOS polygenic risk scores (PCOS$_{PRS}$). The regressions were adjusted for median age and the first 10 principal components. SE = standard error; OR = odds ratio; LCI = lower confidence interval; UCI = upper confidence interval.

Algorithm	Cases	Controls	Estimate	SE	P	OR	LCI	UCI	r²	
European										
Coded Broad	1878	5052	0.04	0.03	0.235	1.04	0.98	1.10	0.0003	
Coded Strict	366	5052	0.19	0.06	0.002	1.21	1.07	1.36	0.0046	*
Regex Broad	332	5052	0.26	0.06	4.6E-5	1.29	1.14	1.46	0.0083	**
Regex Strict	245	5052	0.21	0.07	0.004	1.23	1.07	1.42	0.0049	
Non-European										
Coded Broad	741	1309	0.09	0.10	0.354	1.10	0.90	1.33	0.0006	
Coded Strict	126	1309	0.32	0.20	0.111	1.38	0.93	2.04	0.0039	
Regex Broad	103	1309	0.28	0.22	0.208	1.32	0.86	2.04	0.0027	
Regex Strict	77	1309	0.21	0.25	0.404	1.24	0.75	2.03	0.0014	
Multi-Ancestry										
Coded Broad	2228	4907	0.08	0.05	0.114	1.08	0.98	1.20	0.0005	
Coded Strict	419	4907	0.40	0.10	8.7E-5	1.49	1.22	1.81	0.0068	**
Regex Broad	382	4907	0.34	0.10	0.001	1.41	1.15	1.73	0.0050	*
Regex Strict	281	4907	0.36	0.12	0.003	1.44	1.13	1.82	0.0050	

Figure 1. PCOS algorithm pipeline. This schematic illustrates the algorithm development steps for the controls and the four PCOS algorithms. The Venn diagram illustrates how the algorithm datasets are nested within one another. Each color corresponds with one of the algorithm datasets. ICD = International classification of disease, 9th and 10th revision.

Figure 2. Laboratory measurements for PCOS algorithm cases and controls. Boxplots of (a) BMI measurements, (b) insulin levels, (c) estradiol levels, and (d) free testosterone levels for PCOS algorithm cases and controls. Colored boxes represent races. Boxes represent the individuals with lab measurements in the 25th and 75th percentile. Lines above and below the boxes represent the 95th and 5th quartiles. Lines within each box mark the median. Wilcoxon rank-sum tests were performed between algorithm cases and controls and Brackets display the p-values of the statistical test. BMI= body mass index.

Figure 3. Comparison of laboratory measurements between White, African American, and Hispanic PCOS algorithm cases and controls. Boxplots of (a) BMI measurements, (b) insulin levels, (c) estradiol levels, and (d) free testosterone levels for White, African American, and Hispanic PCOS cases and controls. Colors correspond with each race. Boxes represent the 25th and 75th quartiles. Lines above and below the boxes represent the 95th and 5th quartiles. Lines within each box mark the median. Wilcoxon rank-sum tests were performed between races within the PCOS cases and control datasets. Brackets display the p-values of the statistical test. BMI= body mass index; W = White; AA = African American; HIS = Hispanic.

Figure 4. Race stratified laboratory measurements for PCOS algorithm cases and controls. Boxplots of (a) BMI measurements, (b) insulin levels, (c) estradiol levels, and (d) free testosterone levels of race stratified PCOS algorithm datasets. Each color corresponds with a race. Boxes represent the 25th and 75th quartiles. Lines above and below the boxes represent the 95th and 5th quartiles. Lines within each box mark the median. Wilcoxon rank-sum tests were performed between algorithm cases and controls within each race. Brackets display the p-values of the statistical test. BMI= body mass index; CN = controls; CB = coded broad; CS = coded strict; RB = regex broad; RS = regex strict.

Figure 5. Genetic validation of PCOS algorithms. Logistic regressions were performed between PCOS case status and PCOS polygenic risk scores (PCOS$_{PRS}$). The regression models were adjusted for median age and the first 10 principal components. P-values are displayed for each regression model. Colors correspond to the genotyped sample used in the analysis. OR = odds ratio.